Participated · Series A · Aug 2026

Mindgard operationalizes AI security research and offensive-security expertise through a Security Platform that performs Shadow AI discovery, AI red teaming, and run-time AI protection across models, agents, and applications. The company was spun out of over a decade of AI security research at Lancaster University and is headquartered in Boston and London. Mindgard's platform has been used to uncover and publicly disclose more than 150 high-impact security and safety vulnerabilities in widely used AI products, including a zero-day code execution vulnerability in Cursor IDE, a trusted workspace flaw in Google Antigravity, and image-generation guardrail failures in ChatGPT. Its customer base includes a large number of Fortune 2000 companies and AI innovators across financial services, pharmaceuticals, gaming, digital services, semiconductors, and healthcare. The company plans to scale product, engineering, sales, and marketing following its $30M Series A to meet significant enterprise demand.

Participated · Equity · Jun 2026

NeuroBell develops LUNA, a battery-powered, WiFi-connected neonatal electroencephalogram (EEG) system that provides bedside, clinical-grade brain monitoring. LUNA features an eight-channel EEG amplifier, 10-20 EEG electrode placement for neonates, a two-button setup to begin recording, and continuous impedance checks. The system offers automated neonatal seizure detection to support quicker identification of seizures and decision-making by NICU staff. NeuroBell says LUNA enables quick setup and recording for NICU teams regardless of size or location and supports continuous monitoring at the bedside. The company is based in Cork, Ireland, and is anticipating FDA clearance in the coming months. NeuroBell raised $5.5 million in a financing led by Elkstone, with participation from Parkview Health and existing investors to support clinical deployment and U.S. market entry.

Participated · Equity · Jun 2026

Ubotica builds Orbital AI that runs AI-powered analysis directly in orbit to reduce response times and improve satellite network efficiency. Its flagship Live Maritime Intelligence platform continuously detects emerging maritime threats, identifies areas of elevated risk, and autonomously tasks satellites and sensors for faster operational intelligence. The company positions its offering to help governments and operators protect critical maritime infrastructure such as undersea cables, offshore energy assets, and shipping routes. Ubotica plans to accelerate commercial deployment and expand LMI rollout following the $11M raise. The financing will also support continued development of its in-orbit AI and autonomous tasking capabilities. The articles do not disclose revenue, users, or other operating metrics.

Led · Equity · Apr 2026

Vertigenius develops a wearable head-sensor medical device and platform that enables clinicians to remotely monitor vertigo patients and track treatment progress. The company registered with the FDA and launched in the US in October, where 20 clinics in 11 states have used its device to treat around 3,000 patients. Vertigenius says its platform accelerates clinician workflows, reduces clinic visits, and enables clinics to access additional insurance reimbursement for remote monitoring in the US. The company positions the US as an addressable market of over €3bn with more than 5,000 vestibular clinics and plans to grow its US commercial presence. With a €2.55m raise following a €2.1m round in 2024, Vertigenius will hire across clinical research, product R&D, quality assurance and regulatory affairs while maintaining its Irish headquarters. Vertigenius aims to expand further across Europe and into Asia Pacific over the next five years.

Participated · Series E · Feb 2026

Founded in 2017 and based in Palo Alto, SambaNova designs and sells AI systems such as the SN40L and the next-generation SN50 for high-performance inference and model serving. The SN40L launched in September 2023 and became available on-premises in November 2023; the SN50 was unveiled in February 2026 and is due to begin shipping to customers in the second half of 2026 with SoftBank as its first deployment partner. SambaNova positions itself as a provider of “premium inference,” claiming the ability to fit multi-trillion-parameter models onto a single rack to run them quickly. The company has commercial wins including JPMorgan Chase, Saudi Aramco, Intel, and other Japanese firms. It has a multi-year partnership with Intel that includes co-developing products and go-to-market efforts, and it says current funding will help scale operations and secure its supply chain to meet strong demand.